

FOR IMMEDIATE RELEASE

**CVie Therapeutics obtained approval from the Ministry of Health and Welfare
for conducting Phase 2b Clinical Trial of Rostafuroxin in Taiwan**

Hong Kong, August 3, 2015—Lee's Pharmaceutical Holdings Limited ("Lee's or the Group") (Main Board Stock Code: 0950; Website: www.leespharm.com) today announced that, CVie Therapeutics Limited ("CVie"), the Group's subsidiary has successfully obtained the approval for a global Phase II clinical study (Protocol No. CVT-CV-001) in Taiwan for one of its portfolio products Rostafuroxin capsule 50, 500ug with antihypertensive effect.

CVie has successfully achieved the official Approval Notice (No. 1046044455) from the Ministry of Health and Wealth ("MOHW") in Taiwan for its application of a Phase II multi-centers clinical study on Rostafuroxin of different doses in comparison with Losartan[®], assessed by office and ambulatory blood pressure monitoring in a hypertensive population selected according to a specific genetic profile. The Taiwan study is a part of global Phase IIb study of Rostafuroxin. Currently, the Italian arm of the study is ongoing and has so far completed 70% of the targeted enrollment of 160 patients.

"We are thrilled of reaching this important milestone for Rostafuroxin, and this is indeed a monumental achievement for CVie's Taiwan team," said Dr. Benjamin Li, Chief Executive officer of the Group. "We are looking forward to starting the Taiwan arm of the study as soon as possible."

About Rostafuroxin

Rostafuroxin is a digitoxygenin derivative that selectively disrupts the mutant adducin and the ouabain-activated Na(+)/K(+)-pump binding to Src-SH2 domain without affecting the binding of normal proteins. Rostafuroxin is endowed of high potency and efficacy in reducing blood pressure and preventing organ hypertrophy in animal models representative of both adducin and EO mechanisms, by oral treatment. It is indicated for treatment of newly diagnosed hypertension patients who carry certain genetic profiles representative of adducing and EO-hypertensive mechanisms. The personalized treatment of hypertension could signify a shift of paradigm in hypertension treatment.

FOR IMMEDIATE RELEASE

About Lee's Pharmaceutical

Lee's Pharm is a research-based biopharmaceutical company listed in Hong Kong with over 20 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's Pharm focuses on several key disease areas such as cardiovascular diseases, oncology, gynecology, dermatology and ophthalmology. Lee's Pharm development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspires to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.

About CVie

CVie is a joint venture between Lee's Pharmaceutical Holdings Ltd. and a reputable US venture capital and is a stand-alone drug development company specialized in cardiovascular diseases. CVie owns two phase II assets that target cardiovascular disease with significant unmet medical need.

Safe Harbor Statement

The performance and the results of operation of Lee's during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's nor the Directors, employees or agents of Lee's assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialise or turns out to be incorrect.

For further information, please contact: Vivian Fung

Tel: (852)2314-1282 /Fax: (852)2314-1708

Email: info@leespharm.com